AbbVie Beats Estimates as Sales of Humira Continues Climb

AbbVie Inc., the drugmaker carved out of Abbott Laboratories at the start of the year, reported profit that beat analysts’ estimates and raised its 2013 forecast after sales of top medicine Humira gained on price increases and new indications.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.